The company’s strategic portfolio proved to be the primary engine of this growth, expanding by 53 percent to SEK 5,095 million. Haematology sales reached SEK 5,726 million, while immunology operations contributed SEK 1,711 million. These figures pushed the adjusted EBITA margin to 35 percent, with earnings per share before dilution rising to SEK 3.17 compared to SEK 1.85 in the same period last year.

Beyond financial gains, Sobi reported mixed results in its clinical pipeline. While the company received a Complete Response Letter regarding manufacturing processes for its uncontrolled gout treatment, it simultaneously announced positive topline data from the Phase 3 REDUCE 2 study of Pozdeutinurad. Bolstered by these results, Sobi management raised its full-year 2026 outlook, now anticipating revenue growth in the mid-to-high teens and an adjusted EBITA margin reaching the mid-to-high 30s.